NCT05726825 Efficacy of Add-on Plasma Exchange As an Adjunctive Strategy Against Septic Shock
| NCT ID | NCT05726825 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hannover Medical School |
| Condition | Septic Shock |
| Study Type | INTERVENTIONAL |
| Enrollment | 274 participants |
| Start Date | 2025-02-19 |
| Primary Completion | 2028-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 274 participants in total. It began in 2025-02-19 with a primary completion date of 2028-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Randomized, prospective, multicenter, open-label, controlled, parallel-group interventional trial to test the adjunctive effect of therapeutic plasma exchange in patients with early septic shock.
Eligibility Criteria
Inclusion Criteria: * New onset of septic shock (\< 24 hrs), (SEPSIS-3 definition) * Norepinephrine (NE) dose ≥ 0.4 μg/kg/min ≥ 30 min OR NE ≥ 0.3 μg/kg/min + vasopressin (any dose) * Established vascular access suitable for plasma exchange independent of study inclusion (due to established indication of RRT, expected need for RRT within the next 48 hours or other medical reasons as assessed by treating physician team) Exclusion Criteria: * Age \< 18 or \> 80 years * Urogenital focus of infection * Pregnancy * Heparin-induced thrombocytopenia * Known reaction against fresh frozen plasma (FFP)
Contact & Investigator
Sascha David, Prof. Dr.
PRINCIPAL INVESTIGATOR
University of Zurich
Frequently Asked Questions
Who can join the NCT05726825 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Septic Shock. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05726825 currently recruiting?
Yes, NCT05726825 is actively recruiting participants. Contact the research team at sascha.david@usz.ch for enrollment information.
Where is the NCT05726825 trial being conducted?
This trial is being conducted at Innsbruck, Austria, Vienna, Austria, Berlin, Germany, Berlin, Germany and 11 additional locations.
Who is sponsoring the NCT05726825 clinical trial?
NCT05726825 is sponsored by Hannover Medical School. The principal investigator is Sascha David, Prof. Dr. at University of Zurich. The trial plans to enroll 274 participants.